A longitudinal study assessing Aspergillus PCR performance through participation of external quality assessment schemes from 2019 to 2022

Ricketts, Alastair
Montgomery, Dorothy
Loeffler, Juergen
Barnes, Rosemary
Cruciani, Mario
Donnelly, J Peter
White, P Lewis

QCMD, Glasgow, Scotland, UK
QCMD, Glasgow, Scotland, UK
Medizinische Klinik II, Labor WÜ4i, Universitätsklinikum Würzburg, Germany
Cardiff University, Cardiff, UK
The Fungal PCR Initiative, Verona, Italy
The European Aspergillus PCR Initiative, de Hoefkamp 1096, 6545 MD Nijmegen, The Netherlands
Public Health Wales Mycology Reference Laboratory and Cardiff University Centre for trials research, University Hospital of Wales, Heath Park, Cardiff, UK

Corresponding author: Professor P. Lewis White, Public Health Wales Mycology Reference Laboratory, PHW Microbiology Cardiff, University Hospital of Wales, Heath Park, Cardiff, UK, CF14 4XW. Tel: +44 (0)29 2074 6581; E-mail: [email protected]

Medical Mycology Publish Ahead of Print, April 11, 2025. | DOI: 10.1093/mmy/myaf036

Lay Summary

Aspergillus PCR has recently gained widespread acceptance following extensive validation and development of commercial assays. The analysis of data from external quality assessment schemes shows that centres new to Aspergillus PCR testing should potentially use commercial tests.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)